Sanguina, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sanguina, Inc. - overview
Established
2014
Location
Atlanta, GA, US
Primary Industry
Medical Devices & Equipment
About
Sanguina, Inc. , based in the US, develops advanced blood health monitoring solutions aimed at improving individual health management, with a focus on anemia detection through innovative technologies. Founded in 2014 in Atlanta, US, Sanguina, Inc. specializes in blood health monitoring solutions.
The company was co-founded by Andrew Lyon, Erika Tyburski, Tom Stribling, and Wilbur Lam, with Erika Tyburski currently serving as CEO. Sanguina has successfully raised USD 2. 8 mn in its Series A funding round, led by Veritus Capital Partners Co. , Ltd.
, and has completed a total of 4 deals, the most recent being on 2023-07-25. The firm has not undergone any major pivots or changes in business strategy since its inception. Sanguina Inc. specializes in innovative blood health monitoring solutions, primarily through its flagship product, AnemoCheck.
This at-home testing system enables users to assess their blood health, specifically targeting anemia, which affects over 1. 9 billion individuals globally. The AnemoCheck product line includes both home-use and mobile versions, providing accessible, affordable testing options for proactive health management. Sanguina targets individuals experiencing anemia symptoms, healthcare providers, and wellness advocates interested in preventative health measures across North America, Europe, and select regions in Asia.
Sanguina generates revenue through direct-to-consumer sales of its AnemoCheck products and potential partnerships with healthcare organizations and retailers. Customers purchase testing kits for easy home use, and transactions are facilitated through online sales via Sanguina's website. The firm may also explore subscription models for ongoing health assessments and collaborations with healthcare systems for broader integration into patient care programs. In July 2023, Sanguina, Inc.
raised USD 2. 8 mn in Series A funding to accelerate product development and support expansion efforts. The company plans to introduce new product lines and improve existing offerings to enhance user experience. Sanguina aims to expand its market reach further into Europe and Asia by the end of 2024, leveraging the recent funding to drive these initiatives.
Current Investors
XRC Labs, The Seed Lab, National Science Foundation
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Monitoring Equipment, Medical Software, Analytics & Performance Software
Website
www.sanguina.com
Verticals
Manufacturing, Mobile Apps
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.